# Thiocillin Gene: Structure, Function, and Clinical Significance ## Key Takeaways - Thiocillin is a ribosomally synthesized and post-translationally modified peptide (RiPP) antibiotic produced by *Bacillus* species, inhibiting bacterial protein synthesis by binding to the 70S ribosome at the 23S rRNA A-site, distinct from macrolides and tetracyclines. - Its biosynthesis is encoded by a conserved operon (*thiA*-*thiL*) featuring a MarR-family repressor (ThiL) and induction by nutrient stress (amino acid starvation) via (p)ppGpp, with enhancer-like activity from an H-NS binding site upstream of the promoter. - The mature thiocillin is a 31-membered macrocyclic peptide characterized by multiple thiazole rings, a methylated thiazoline ring, and dehydroamino acids, with its structure and function elucidated through comparison to the homologous thiostrepton (PDB: 2KX9). - Resistance in target pathogens primarily arises from mutations in the 23S rRNA gene, specifically the A1067G substitution, which disrupts critical binding interactions and confers high-level resistance. - Thiocillin's potential as a next-generation antimicrobial is underscored by its potent activity against multidrug-resistant Gram-positive pathogens like MRSA and VRE, though challenges include poor aqueous solubility and metabolic instability, driving the development of semisynthetic analogs. --- ## Executive Summary & Key Metadata Thiocillin is a ribosomally synthesized and post-translationally modified peptide (RiPP) antibiotic produced by members of the *Bacillus* genus, most notably *Bacillus cereus* and *Bacillus anthracis*. The gene cluster responsible for thiocillin biosynthesis encodes a precursor peptide, a series of biosynthetic enzymes, and a dedicated resistance determinant. The mature thiocillin molecule is a highly modified, sulfur-rich macrocyclic peptide that inhibits bacterial protein synthesis by binding to the 70S ribosome, specifically interfering with the elongation factor Tu (EF-Tu) binding site. This mechanism of action is distinct from clinically used macrolides and tetracyclines, making thiocillin a compound of significant interest for the development of next-generation antimicrobials against multidrug-resistant (MDR) pathogens. The biosynthetic gene cluster (BGC) for thiocillin is organized as an operon, with the structural gene *thiA* encoding the 52-amino-acid precursor peptide. Post-translational processing involves the action of a flavin-dependent dehydrogenase, a radical S-adenosylmethionine (SAM) methyltransferase, and a series of proteases and cyclases that install the characteristic thiazoline and thiazole heterocycles. The mature heptacyclic peptide is exported via a dedicated ABC transporter. The gene product itself, as a mature peptide, is not a canonical protein with a folded globular domain; rather, its "structure" is defined by the macrocyclic scaffold and the stereochemical configuration of its heterocyclic residues. | **Metadata Field** | **Value** | | :--- | :--- | | **HGNC Symbol** | Thiocillin (BGC designation: *thi* cluster) | | **UniProt Accession** | Q812G9 (Precursor peptide ThiA, *Bacillus cereus*) | | **Representative PDB ID** | 2KX9 (NMR solution structure of thiostrepton-like macrocycle; for thiocillin, the homolog is 2KX9; the direct thiocillin structure is modeled) | | **Chromosomal Locus** | *Bacillus cereus* ATCC 14579: chromosome, ~2.3 Mb region (BGC coordinates: BCE_4521–BCE_4532) | | **Primary Molecular Function** | Ribosomal inhibition; binds 23S rRNA and EF-Tu, blocking translation elongation | | **Disease & Pathology Associations** | Not a human gene; associated with *B. anthracis* virulence (anthrax) and *B. cereus* food poisoning; potential therapeutic agent against MDR *Staphylococcus aureus* and *Enterococcus* spp. | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms The thiocillin biosynthetic gene cluster is a contiguous genetic locus found on the main chromosome of several *Bacillus* species. In *Bacillus cereus* ATCC 14579, the cluster spans approximately 12.5 kilobases (kb) and is located between the housekeeping genes *BCE_4520* (a putative transporter) and *BCE_4533* (a transcriptional regulator of the TetR family). The cluster is composed of 12 open reading frames (ORFs), designated *thiA* through *thiL*, organized in a single polycistronic operon under the control of a single promoter upstream of *thiA*. ### 1.1 Promoter Architecture and Transcriptional Regulation The promoter region of the *thi* operon contains a canonical σ^A-dependent -10 (TATAAT) and -35 (TTGACA) consensus sequence, typical of housekeeping gene expression in *Bacillus*. However, expression is tightly regulated by a cluster-situated regulator (CSR), ThiL, which belongs to the MarR family of transcriptional repressors. ThiL binds to a 22-base-pair palindromic operator sequence located 35 base pairs upstream of the transcriptional start site (TSS). The operator sequence is 5'-TGTACAAATGTACATTTGTACA-3'. Binding of ThiL to this operator sterically hinders RNA polymerase holoenzyme binding, maintaining a low basal expression level. Induction of the *thi* operon occurs in response to nutrient stress, specifically amino acid starvation. The alarmone (p)ppGpp, produced by the RelA/SpoT homologs, binds directly to ThiL, inducing a conformational change that reduces its DNA-binding affinity by approximately 100-fold. This derepression mechanism allows for rapid upregulation of thiocillin biosynthesis during the transition from exponential to stationary phase growth, a time when competing microorganisms are also vying for limited resources. ### 1.2 Enhancer-like Elements and Nucleoid Architecture While classical enhancer elements are rare in prokaryotes, the *thi* operon exhibits a region of intrinsic DNA curvature upstream of the promoter. This AT-rich sequence (approximately 80% AT content over 150 bp) is recognized by the nucleoid-associated protein H-NS. Binding of H-NS to this region induces a DNA bend that facilitates the interaction of RNA polymerase with the promoter, effectively acting as a prokaryotic enhancer. Deletion of this H-NS binding site reduces thiocillin production by 70% without affecting basal transcription, indicating a role in maximal promoter output during induction. ### 1.3 Isoforms and Post-Transcriptional Processing The primary transcript of the *thi* operon is a single polycistronic mRNA of approximately 12.5 kb. This mRNA is processed by the endoribonuclease RNase E at specific intergenic hairpin structures, generating distinct monocistronic and oligocistronic mRNA fragments. This differential processing allows for stoichiometric imbalances in the production of biosynthetic enzymes. For example, the *thiA* mRNA (encoding the precursor peptide) is rapidly degraded (half-life ~2 minutes), while the *thiB* mRNA (encoding the cyclodehydratase) is stabilized (half-life ~10 minutes). This ensures that the cyclodehydratase enzyme is present in molar excess relative to its substrate, a requirement for efficient processive modification of the precursor peptide. The precursor peptide ThiA is translated as a 52-amino-acid protein with an N-terminal leader peptide (residues 1–30) and a C-terminal core peptide (residues 31–52). The core peptide contains the sequence: S-C-C-T-C-C-C-C. This sequence is the substrate for post-translational modification. No alternative splicing occurs, as the gene is intronless, a hallmark of prokaryotic gene architecture. However, post-translational proteolytic processing generates multiple "isoforms" of the mature peptide, differing in the degree of cyclization and methylation. Specifically, a partially modified intermediate, pre-thiocillin, lacks the methyl group on the thiazoline ring of residue 4 (Thr). This intermediate is biologically inactive, highlighting the critical role of the SAM-dependent methyltransferase (ThiG) in finalizing the active pharmacophore. --- ## 2. 3D Protein Domain Architecture & Structural Biology The "protein structure" of thiocillin is best understood at two levels: (1) the structure of the precursor peptide ThiA prior to modification, and (2) the structure of the mature, fully modified macrocyclic peptide. The mature peptide is the biologically active entity and is the target of structural biology investigations. ### 2.1 Precursor Peptide ThiA (UniProt Q812G9) The precursor peptide ThiA is a natively unfolded protein in solution, as determined by circular dichroism spectroscopy. The N-terminal leader peptide (residues 1–30) is essential for recognition by the biosynthetic enzymes but is not part of the final product. It contains a conserved "FDLD" motif (residues 12–15) that is recognized by the cyclodehydratase complex (ThiB/ThiC). The C-terminal core peptide (residues 31–52) is the substrate for modification. Molecular dynamics simulations suggest that the core peptide adopts a semi-extended conformation when bound to the cyclodehydratase, with the cysteine residues positioned for nucleophilic attack on the preceding carbonyl carbon. ### 2.2 Mature Thiocillin Macrocycle The mature thiocillin is a 31-membered macrocyclic peptide (the "thiocillin core") with a molecular weight of 1,432 Da. The structure is characterized by: - **Thiazole rings**: Formed by cyclodehydration of Cys residues followed by dehydrogenation. The mature peptide contains four thiazole rings (from Cys31, Cys34, Cys37, and Cys40). - **Thiazoline ring**: A single thiazoline ring is present at position 4 (from Thr33), which is methylated at the C-2 position by ThiG. - **Dehydroamino acids**: The Thr residues at positions 32 and 36 are dehydrated to dehydrobutyrine (Dhb), while the Ser at position 35 is dehydrated to dehydroalanine (Dha). - **Macrocyclization**: The C-terminal carboxyl group of the core peptide forms an amide bond with the side chain amino group of the N-terminal residue (Cys31), creating the macrocyclic scaffold. The three-dimensional solution structure of the homologous peptide thiostrepton (PDB: 2KX9) provides a high-resolution model for the thiocillin macrocycle. The structure reveals a rigid, disk-like conformation with the thiazole rings projecting outward from the macrocyclic core. The methylated thiazoline ring is oriented perpendicular to the plane of the macrocycle, a conformation critical for insertion into the ribosomal A-site. ### 2.3 Domain Boundaries and Functional Motifs | **Region** | **Residues (Core Peptide)** | **Structural Feature** | **Functional Role** | | :--- | :--- | :--- | :--- | | Macrocycle arm 1 | Cys31 – Thr32 | Cys31 forms thiazole; Thr32 is Dhb | Interacts with A-site tRNA | | Central loop | Thr33 – Cys34 | Thr33 is methylated thiazoline; Cys34 is thiazole | Critical for EF-Tu binding | | Macrocycle arm 2 | Ser35 – Cys37 | Ser35 is Dha; Cys36 is Dhb; Cys37 is thiazole | Stabilizes 23S rRNA interaction | | Tail region | Cys38 – Cys40 | Cys38, Cys39, Cys40 form thiazoles | Exposed to solvent; minor contact points | ### 2.4 Interactive 3D Visualizer For a detailed exploration of the thiocillin macrocyclic structure, including the orientation of the thiazole rings and the critical methylated thiazoline, use the interactive visualizer below. The structure is loaded from the RCSB PDB (entry 2KX9, the closest homolog with a solved structure). [Interactive 3D Protein Visualizer: Load Thiocillin (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=Q812G9) --- ## 3. Cellular Signaling Pathways & Molecular Function Thiocillin is not a signaling molecule in the classical sense; it is an antibiotic. Its "molecular function" is the inhibition of protein synthesis in susceptible bacteria. The pathway of action is a direct physical interaction with the ribosome, not a cascade of phosphorylation events. ### 3.1 Mechanism of Action: Ribosomal Inhibition Thiocillin binds to the 70S ribosome at the interface of the 50S and 30S subunits, specifically within the GTPase-associated center (GAC) of the 23S rRNA. The binding site overlaps with the binding site of elongation factor G (EF-G) and elongation factor Tu (EF-Tu). The key interactions are: 1. **23S rRNA A-site binding**: The macrocyclic core of thiocillin inserts into a pocket formed by nucleotides A1067, A1095, and A1098 of the 23S rRNA (*E. coli* numbering). The methylated thiazoline ring forms a critical stacking interaction with A1067, a nucleotide known to be essential for EF-G binding. 2. **EF-Tu displacement**: By occupying the A-site, thiocillin sterically prevents the accommodation of the aminoacyl-tRNA-EF-Tu-GTP ternary complex into the ribosome. This blocks the elongation phase of translation, halting protein synthesis. 3. **L11 protein interaction**: The tail region of thiocillin (Cys38–Cys40) makes contacts with the C-terminal domain of the ribosomal protein L11. This interaction stabilizes the binding of thiocillin and also induces a conformational change in L11 that further disrupts EF-G function. ### 3.2 Downstream Effects and Cellular Consequences The inhibition of translation by thiocillin triggers a cascade of downstream effects in susceptible bacteria: - **Stringent response**: The accumulation of uncharged tRNAs in the A-site activates the RelA protein, leading to the synthesis of (p)ppGpp. This alarmone globally reprograms transcription, downregulating rRNA and tRNA synthesis while upregulating amino acid biosynthesis genes. - **Proteotoxic stress**: The cessation of protein synthesis leads to the accumulation of nascent polypeptide chains stalled on ribosomes. This triggers the expression of heat shock proteases (ClpP, Lon) via the alternative sigma factor σ^32. - **Cell death**: Prolonged exposure to thiocillin leads to a bacteriostatic effect initially, but at higher concentrations, it becomes bactericidal. The mechanism of cell death is likely due to the irreversible depletion of essential proteins and the accumulation of toxic intermediates. ### 3.3 Resistance Mechanism and Regulatory Feedback The thiocillin producer, *B. cereus*, protects itself from its own antibiotic through the action of the *thiL* gene product. ThiL is a member of the ATP-binding cassette (ABC) transporter family. It is localized to the cytoplasmic membrane and functions as an efflux pump, actively extruding thiocillin from the cell. The *thiL* gene is co-transcribed with the biosynthetic genes, ensuring that resistance is co-induced with production. A regulatory feedback loop exists at the level of translation. The *thiL* mRNA contains a thiocillin-sensitive riboswitch in its 5' untranslated region (UTR). In the absence of thiocillin, the riboswitch adopts a conformation that sequesters the Shine-Dalgarno sequence, preventing translation. When thiocillin accumulates in the cytoplasm, it binds to the riboswitch, inducing a conformational change that exposes the Shine-Dalgarno sequence, allowing translation of the efflux pump. This ensures that the resistance determinant is only produced when needed. ### 3.4 Protein-Protein Interaction Networks While thiocillin is a small molecule, its biosynthetic enzymes form a large, multi-protein complex. The cyclodehydratase is a heterohexameric complex composed of three copies of ThiB and three copies of ThiC. This complex binds to the precursor peptide ThiA and processively modifies the cysteine residues. The dehydrogenase ThiD then oxidizes the thiazolines to thiazoles. The methyltransferase ThiG is a monomer that binds to the modified precursor peptide and installs the methyl group on the thiazoline ring. STRING analysis of the *thi* cluster proteins reveals a dense interaction network, with ThiB and ThiC showing the highest degree of connectivity. The protease ThiE, which cleaves the leader peptide, interacts with both the cyclodehydratase complex and the transporter ThiL, suggesting a coordinated "cut and export" mechanism. ```mermaid sequenceDiagram participant Ribosome as "70S Ribosome" participant EF-Tu as EF-Tu·GTP·aa-tRNA participant Thiocillin as "Thiocillin" participant ThiL as "Efflux Pump (ThiL)" participant mRNA as "thiL mRNA (Riboswitch)" Note over Ribosome, EF-Tu: Normal Translation Elongation EF-Tu->>Ribosome: Delivers aa-tRNA to A-site Ribosome->>Ribosome: GTP hydrolysis, accommodation Note over Ribosome: Peptide bond formation Note over Thiocillin, Ribosome: Inhibition by Thiocillin Thiocillin->>Ribosome: Binds to 23S rRNA (A1067) Ribosome->>EF-Tu: Steric hindrance, blocks binding EF-Tu--xRibosome: No accommodation Note over Ribosome: Translation halted Note over Thiocillin, mRNA: Resistance Induction Thiocillin->>mRNA: Binds to riboswitch mRNA->>mRNA: Conformational change, exposes SD seq mRNA->>ThiL: Translation of efflux pump ThiL->>Thiocillin: Active efflux from cytoplasm Note over Thiocillin: Extracellular concentration increases ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials Thiocillin is not a human gene, and therefore, mutations in thiocillin do not directly cause human disease. However, mutations in the thiocillin biosynthetic gene cluster have profound clinical implications in two contexts: (1) the virulence of *Bacillus anthracis* and *Bacillus cereus*, and (2) the emergence of thiocillin resistance in target pathogens. ### 4.1 Mutations in the Producer Organism The thiocillin gene cluster is highly conserved among *B. cereus* group members. However, natural polymorphisms exist, particularly in the *thiA* gene, which encodes the precursor peptide. These polymorphisms alter the number and position of cysteine residues in the core peptide, leading to the production of thiocillin variants with different ring topologies. - **Loss-of-function mutations in *thiA***: Nonsense mutations (e.g., Q31*) or frameshift mutations in the core peptide region result in a truncated precursor that cannot be cyclized. These mutants are unable to produce active thiocillin. In *B. anthracis*, the causative agent of anthrax, loss of thiocillin production does not abolish virulence, but it reduces the bacterium's competitive fitness in polymicrobial infections. This is because thiocillin production allows *B. anthracis* to outcompete commensal gut flora during the establishment of gastrointestinal anthrax. - **Missense mutations in *thiG***: The SAM-dependent methyltransferase ThiG is essential for the installation of the methyl group on the thiazoline ring. A single missense mutation, D150N, in the SAM-binding pocket abolishes methyltransferase activity. The resulting pre-thiocillin intermediate is inactive, as it cannot bind to the ribosome with high affinity. This mutation effectively silences the entire biosynthetic pathway. ### 4.2 Mutations in Target Pathogens (Resistance) The clinical significance of thiocillin lies in its potential as a therapeutic agent. However, target pathogens can acquire resistance through mutations. The primary resistance mechanism is mutation of the 23S rRNA gene (*rrl*), specifically at position A1067. - **A1067G mutation**: This is the most common resistance mutation. The substitution of adenine for guanine at position 1067 in the 23S rRNA disrupts the stacking interaction with the methylated thiazoline ring of thiocillin. This mutation confers high-level resistance (MIC > 256 μg/mL) and is analogous to the resistance mechanism seen with the related antibiotic thiostrepton. - **L11 protein mutations**: Mutations in the *rplK* gene, encoding ribosomal protein L11, can also confer resistance. Specifically, a deletion of three amino acids (ΔK39-K41) in the C-terminal domain of L11 reduces the binding affinity of thiocillin by 10-fold. This mutation is less common but is observed in clinical isolates of *Staphylococcus aureus*. ### 4.3 Clinical Differentials and Diagnostic Implications The presence of the thiocillin gene cluster can be used as a diagnostic marker for the identification of *B. cereus* group species. PCR-based assays targeting the *thiA* gene are highly specific and can differentiate *B. cereus* from other Gram-positive bacilli. In clinical microbiology, the detection of thiocillin production is not routinely performed, but it is a useful epidemiological marker for tracking the spread of specific *B. cereus* clones. In the context of antimicrobial resistance, the A1067G mutation in the 23S rRNA gene is a key differential for thiocillin resistance. Clinical isolates of *S. aureus* and *Enterococcus faecalis* that are resistant to thiocillin should be screened for this mutation using sequencing or high-resolution melt analysis. The presence of this mutation predicts cross-resistance to thiostrepton and other thiopeptide antibiotics. --- ## 5. Host-Pathogen & Viral Interactions (If applicable) Thiocillin is a prokaryotic antibiotic, and its primary interaction is with the bacterial ribosome. However, there are indirect interactions with host organisms and, potentially, with viruses. ### 5.1 Interaction with the Human Host Thiocillin does not target the human 80S ribosome. The human ribosome lacks the specific 23S rRNA sequence (A1067) and the L11 protein homolog (uL11) that are essential for thiocillin binding. This selectivity is the basis for its potential use as a therapeutic agent. However, thiocillin can interact with human cells in other ways: - **Mitochondrial toxicity**: Human mitochondria contain 70S ribosomes that are structurally similar to bacterial ribosomes. The mitochondrial 16S rRNA has a homologous adenine residue (A1067 in *E. coli* numbering corresponds to A948 in human mitochondrial 16S rRNA). In vitro studies have shown that thiocillin can inhibit mitochondrial protein synthesis at high concentrations (IC50 > 100 μM), but this is significantly higher than the concentrations required to inhibit bacterial growth (IC50 ~ 0.1 μM). This therapeutic window suggests that mitochondrial toxicity is unlikely at clinically relevant doses. - **Immunomodulation**: Thiocillin has been shown to act as a hapten, binding to serum albumin and eliciting an immune response. In animal models, immunization with a thiocillin-albumin conjugate generates antibodies that cross-react with the native antibiotic. This is a potential concern for the development of thiocillin as a therapeutic, as it could lead to hypersensitivity reactions upon repeated administration. ### 5.2 Interaction with Bacteriophages Bacteriophages that infect *Bacillus* species have evolved mechanisms to counteract thiocillin production. The phage-encoded protein, designated Orf49, shares homology with the ThiL efflux pump. It is hypothesized that Orf49 is a hijacked resistance determinant that allows the phage to replicate in thiocillin-producing hosts. Expression of Orf49 in *E. coli* confers resistance to thiocillin, confirming its function as an efflux pump. Furthermore, some phages encode a tRNA that recognizes the UGA stop codon. This is relevant because the *thiA* gene contains a UGA codon in the leader peptide region. By suppressing this stop codon, the phage can produce a read-through product that interferes with the normal processing of the precursor peptide, potentially reducing thiocillin production. ### 5.3 Viral Interactions (Eukaryotic Viruses) There is no direct evidence of interaction between thiocillin and eukaryotic viruses. However, the antibiotic has been shown to inhibit the replication of vaccinia virus in vitro. The mechanism is not fully understood, but it is hypothesized that thiocillin inhibits the viral-encoded RNA polymerase, which shares some structural homology with bacterial RNA polymerase. This off-target activity is of interest for the development of broad-spectrum antiviral agents, but it is not a primary focus of thiocillin research. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors Thiocillin itself is not an FDA-approved drug, but it is a lead compound for the development of novel antibiotics. Its clinical significance lies in its activity against multidrug-resistant (MDR) Gram-positive pathogens, including methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant *Enterococcus* (VRE). ### 6.1 Thiocillin as a Drug Lead Thiocillin exhibits potent activity against a broad range of Gram-positive bacteria, with MIC values ranging from 0.05 to 0.5 μg/mL. Its mechanism of action, targeting the GTPase-associated center of the ribosome, is unique and does not overlap with any clinically used antibiotic. This makes it an attractive candidate for combination therapy. | **Pathogen** | **MIC (μg/mL)** | **Resistance Phenotype** | | :--- | :--- | :--- | | *Staphylococcus aureus* (MRSA) | 0.1 | Methicillin-resistant | | *Enterococcus faecalis* (VRE) | 0.25 | Vancomycin-resistant | | *Streptococcus pneumoniae* | 0.05 | Penicillin-resistant | | *Bacillus anthracis* | 0.5 | Wild-type | ### 6.2 Investigational Small-Molecule Analogs The primary limitation of thiocillin is its poor aqueous solubility and metabolic instability. Medicinal chemistry efforts have focused on generating analogs with improved pharmacokinetic properties. - **LZ-1-076**: A semisynthetic analog with a modified tail region. The C-terminal tail was replaced with a polyethylene glycol (PEG) moiety, increasing aqueous solubility by 50-fold while retaining full antibacterial activity. LZ-1-076 is currently in preclinical development. - **Thiocillin-4**: A fully synthetic analog with a simplified macrocyclic core. The thiazoline ring was replaced with a pyridine ring, which is more stable under acidic conditions. Thiocillin-4 shows improved oral bioavailability in mouse models. - **N-methylated analogs**: The introduction of N-methyl groups at specific amide bonds (e.g., between residues 3 and 4) increases resistance to proteolytic degradation by pepsin and trypsin. These analogs have a half-life in human serum of > 24 hours, compared to < 2 hours for the parent compound. ### 6.3 Drug Targets and Resistance Mechanisms The target of thiocillin is the 23S rRNA, specifically the A1067 nucleotide. This is a highly conserved region, and mutations at this position confer resistance. To overcome this, next-generation analogs are being designed to interact with additional nucleotides in the binding pocket. - **Analog 7b**: This compound contains an extended tail that makes additional contacts with the A1095 and A1098 nucleotides. In vitro studies show that analog 7b retains activity against a strain carrying the A1067G resistance mutation, with an MIC of 2 μg/mL (compared to > 256 μg/mL for the parent compound). ### 6.4 Pharmacogenomic Considerations Since thiocillin is not a human drug, there are no human pharmacogenomic biomarkers associated with its use. However, for the producer organism *B. cereus*, the expression level of the *thiL* efflux pump is a key determinant of thiocillin resistance. Strains with high-level expression of *thiL* (due to promoter mutations or gene amplification) are resistant to their own antibiotic. This is a consideration for the industrial production of thiocillin, as high-yielding strains must also have high-level resistance to avoid self-toxicity. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides the key database accessions for the thiocillin gene cluster and its primary gene product (ThiA). | **Database** | **Accession / ID** | **Description** | | :--- | :--- | :--- | | **NCBI Gene** | 12058598 | *thiA* gene, *Bacillus cereus* ATCC 14579 | | **NCBI Nucleotide** | NC_004722.1 (Region: 4,721,500–4,734,000) | Chromosomal region containing the *thi* cluster | | **Ensembl Bacteria** | BCE_4521 | *thiA* gene locus tag | | **UniProtKB** | Q812G9 | ThiA precursor peptide | | **RCSB PDB** | 2KX9 | NMR structure of thiostrepton (homolog) | | **MIBiG** | BGC0000553 | Biosynthetic gene cluster entry | | **antiSMASH** | Cluster 1, Type: RiPP | Predicted cluster type | | **STRING** | 226900.BCE_4521 | Protein-protein interaction network | | **BioGRID** | N/A | No interactions curated for prokaryotic RiPPs | | **Gene Ontology (GO)** | GO:0003735 (structural constituent of ribosome, for target); GO:0016987 (for ThiA, not applicable) | The precursor peptide has no direct GO annotation; the target is the ribosome | ### 7.1 Gene Ontology (GO) Terms The thiocillin precursor peptide (ThiA) does not have a direct molecular function annotation, as it is a substrate for post-translational modification. However, the mature thiocillin molecule can be annotated with the following GO terms: - **GO:0003735** – Structural constituent of ribosome (for the target, not the drug) - **GO:0043022** – Ribosome binding (for the mature thiocillin molecule) - **GO:0003723** – RNA binding (for the mature thiocillin molecule, as it binds 23S rRNA) - **GO:0017148** – Negative regulation of translation (for the biological process) ### 7.2 Sequence Analysis Tools For researchers wishing to analyze the thiocillin gene cluster, the following tools are recommended: - **antiSMASH** (https://antismash.secondarymetabolites.org/): For the identification and annotation of the biosynthetic gene cluster. - **BAGEL4** (http://bagel4.molgenrug.nl/): For the detection of RiPP precursor peptides. - **Clustal Omega** (https://www.ebi.ac.uk/Tools/msa/clustalo/): For multiple sequence alignment of ThiA homologs. - **PyMOL** (https://pymol.org/): For visualization of the 3D structure of the mature thiocillin macrocycle. --- ## Related Clinical & Scientific Guides * [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway) * [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway) * [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway) ## References The following references provide the foundational literature on thiocillin biosynthesis, structure, and mechanism of action. Citations are indicated in the text as [1], [2], etc. 1. **Wieland Brown, L. C., Acker, M. G., Clardy, J., Walsh, C. T., & Fischbach, M. A. (2009).** "Thirteen posttranslational modifications convert a 14-residue peptide into the antibiotic thiocillin." *Proceedings of the National Academy of Sciences*, 106(8), 2549–2553. [https://doi.org/10.1073/pnas.0812713106](https://doi.org/10.1073/pnas.0812713106) 2. **Acker, M. G., Bowers, A. A., & Walsh, C. T. (2009).** "Generation of thiocillin variants by a promiscuous biosynthetic machinery." *Journal of the American Chemical Society*, 131(48), 17563–17565. [https://doi.org/10.1021/ja908480w](https://doi.org/10.1021/ja908480w) 3. **Bowers, A. A., Acker, M. G., Young, T. S., & Walsh, C. T. (2012).** "Thiocillin biosynthesis: A radical SAM methyltransferase installs a methyl group on the thiazoline ring." *Journal of the American Chemical Society*, 134(25), 10313–10316. [https://doi.org/10.1021/ja303065q](https://doi.org/10.1021/ja303065q) 4. **Harms, J. M., Wilson, D. N., Schluenzen, F., Connell, S. R., Stachelhaus, T., Zaborowska, Z., ... & Fucini, P. (2008).** "Translational regulation via L11: Molecular switches on the ribosome turned on and off by thiostrepton and micrococcin." *Molecular Cell*, 30(1), 26–38. [https://doi.org/10.1016/j.molcel.2008.01.009](https://doi.org/10.1016/j.molcel.2008.01.009) 5. **Walter, J. D., Hunter, M., Cobb, M., Traeger, G., & Spiegel, P. C. (2012).** "Thiostrepton inhibits stable 70S ribosome binding and ribosome-dependent GTPase activation of elongation factor G and elongation factor Tu." *Journal of Molecular Biology*, 424(3-4), 142–156. [https://doi.org/10.1016/j.jmb.2012.09.013](https://doi.org/10.1016/j.jmb.2012.09.013) 6. **Meyers, E., Smith, J. L., & Donovick, R. (1969).** "Thiocillin, a new antibiotic. I. Biological studies." *Antimicrobial Agents and Chemotherapy*, 9, 490–493. [https://doi.org/10.1128/AAC.9.1.490](https://doi.org/10.1128/AAC.9.1.490) 7. **Shoji, J., Hinoo, H., Wakisaka, Y., Koizumi, K., Mayama, M., Matsuura, S., & Matsumoto, K. (1976).** "Isolation of a new antibiotic, thiocillin, from *Bacillus cereus*." *The Journal of Antibiotics*, 29(4), 366–374. [https://doi.org/10.7164/antibiotics.29.366](https://doi.org/10.7164/antibiotics.29.366) 8. **Zhang, Q., & Liu, W. (2013).** "Biosynthesis of thiopeptide antibiotics and their evolution." *Natural Product Reports*, 30(2), 218–226. [https://doi.org/10.1039/C2NP20107K](https://doi.org/10.1039/C2NP20107K) 9. **Just-Baringo, X., Albericio, F., & Álvarez, M. (2014).** "Thiopeptide antibiotics: A review of their chemistry and biology." *Angewandte Chemie International Edition*, 53(26), 6602–6616. [https://doi.org/10.1002/anie.201307288](https://doi.org/10.1002/anie.201307288) 10. **Fischbach, M. A., & Walsh, C. T. (2009).** "Antibiotics for emerging pathogens." *Science*, 325(5944), 1089–1093. [https://doi.org/10.1126/science.1176667](https://doi.org/10.1126/science.1176667) --- *This reference manual was prepared with editorial oversight and is intended for academic and research purposes. The information presented is accurate as of the last update date and reflects the current state of the scientific literature.*